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SUMMARY
The seminal work of Morgan & Rubin (2012) considers rerandomization for all the units at one time.
In practice, however, experimenters may have to rerandomize units sequentially. For example, a clinician
studying a rare disease may be unable to wait to perform an experiment until all the experimental units
are recruited. Our work offers a mathematical framework for sequential rerandomization designs, where
the experimental units are enrolled in groups. We formulate an adaptive rerandomization procedure for
balancing treatment/control assignments over some continuous or binary covariates, using Mahalanobis
distance as the imbalance measure. We prove in our key result, Theorem 3, that given the same num-
ber of rerandomizations (in expected value), under certain mild assumptions, sequential rerandomization
achieves better covariate balance than rerandomization at one time.
Some key words: Experimental design; Mahalanobis distance; Non-central chi-squared; Sequential enrollment.
1. INTRODUCTION
Rerandomization is a method for achieving balanced distributions of covariates across treatment groups
before conducting an experiment (Holschuh, 1980; Urbach, 1985; Imai et al., 2008; Morgan & Rubin,
2012). Despite advocacy for rerandomization dating back to Sir Ronald Fisher, (Savage, 1962, p.88) a
concrete mathematical foundation for rerandomization was only recently developed by the seminal work
of Morgan & Rubin (2012), who advise rerandomization only if “the decision to rerandomize or not is
based on a pre-specified criterion” (Morgan & Rubin, 2012, p.1265). This work has catalyzed a surge of
research in rerandomization, both theoretical and applied in nature. For theoretical contributions, see Li
& Ding (2017) and Morgan & Rubin (2015). For more applied contributions, see Athey & Imbens (2017),
Delavande et al. (2016) and Xu & Kalbfleisch (2013).
The main objective of this work is to balance treatment/control assignments over some continuous (or
binary) covariates by rerandomization. The majority of the traditional randomization procedures are de-
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veloped for only discrete covariates, and continuous covariates are simply discretized by binning. But both
the number and the boundaries of such bins are very difficult to choose, as discussed in Hu & Hu (2012).
Morgan & Rubin (2012) consider rerandomization for a finite sample all recruited at one time using Ma-
halanobis distance as the imbalance measure (henceforth we refer to this as Morgan–Rubin complete
rerandomization). The theoretical advantages of using Mahalanobis distance for continuous covariates are
discussed in Rubin (1979) and Greevy et al. (2004). When the data contains categorical covariates, as
advocated by Morgan & Rubin (2012), we may combine blocking with rerandomization by applying a
stratified randomization procedure to the most important categorical covaraites. However, in practice, a
researcher may be unable to wait to perform an experiment until all experimental units can be recruited,
and thus covariate-adaptive minimization methods (see Lin et al., 2015) might be preferred. To solve this
problem, in this work, we consider rerandomization for sequential enrollment designs where participants
arrive in groups, which we henceforth term sequential rerandomization. To the best of our knowledge,
a mathematical framework for sequential rerandomization has not been previously addressed. A unique
advantage of sequential rerandomization is that while it is adaptive, it still allows for rerandomization,
and thus is much less liable to selection bias than minimization procedures (Berger, 2010). For more
discussion on the relationship between rerandomization and other methods, e.g. finite selection model,
see Morgan & Rubin (2012, Sec. 5).
Given the same number of rerandomizations (in expected value), a seemingly natural conjecture would
be that the balance created by employing Morgan–Rubin complete rerandomization would, in expectation,
be superior to that created using sequential rerandomization, since Morgan–Rubin complete rerandomiza-
tion allows for all possible allocations of units. Under only mild asymptotic conditions, our result in
Theorem 3 proves the opposite to be true (see Section 4). The key mathematical implications for sequen-
tial rerandomization and the results needed to prove Theorem 3 are provided in Sections 2 and 3. Section
5 extends our results to more general settings and concludes the work with a discussion on optimal ran-
domization procedures. All proofs and simulation studies are given in the Supplementary Material.
2. SEQUENTIAL RERANDOMIZATION
Consider a sequential trial in which 2N units are to be divided into K sequential groups, each
group containing 2n1, . . . , 2nK experimental units, where n1 + · · ·+ nK = N . Let the matrix X =
(X1, · · · , XK) ∈ Rp×(2N) be the p covariates for these 2N units where X1, . . . , XK are block matrices
with corresponding dimensions p× 2n1, . . . , p× 2nK ; assumeX1, . . . , Xk are observed sequentially.X
will be treated as fixed and the sample covariance matrix of the kth group, denoted by cov(Xk) (which
has dimension p× p), is assumed to have rank equal to p.
Consider the following rerandomization procedure. For the first group of 2n1 units, we randomly assign
n1 patients to the treatment group and the other n1 to the control group. We denote this randomization
by W ∗1 = (W
∗
1,1, ...,W
∗
1,2n1)
>, a vector of dimension 2n1, where W ∗1,i = 1 if the ith patient of the first
group is assigned to treatment and W ∗1,i = 0 otherwise. Throughout this manuscript, the superscript ∗
denotes results from a tentative allocation, subject to being accepted or rerandomized based on a specific
criterion, whereas results without the superscript ∗ correspond to the actual treatment administered. The
Mahalanobis distance between treatment and control groups corresponding to W ∗1 is
M∗1 =
n1
2
(X¯∗T,1 − X¯∗C,1)>cov(X1)−1(X¯∗T,1 − X¯∗C,1)
where X¯∗T,1 = n
−1
1 X1W
∗
1 and X¯
∗
C,1 = n
−1
1 X1(1−W ∗1 ) are the p-dimensional mean vectors of the
treatment (T) and control (C) groups respectively. This expression is based on the observation that
cov(X¯∗T,1 − X¯∗C,1 | X1) = 2cov(X1)/n1 (see eq. (A1) in Appendix A·2 for details). As in Morgan & Ru-
bin (2012), we let (ϕ1, a1) represent a pre-specified rerandomization criterion such that ϕ1(X1,W ∗1 ) = 1
ifM∗1 < a1 and 0 otherwise (ϕ1 = 1 denotes an acceptable rerandomization). Ifϕ1 = 0,W
∗
1 is not accept-
able and the randomization is repeated; otherwise we set W1 = W ∗1 , M1 = M
∗
1 , X¯T,1 = X¯
∗
T,1, X¯C,1 =
X¯∗C,1 and proceed to consider the second group of 2n2 units. If K = 1, we simply stop and sequential
rerandomization reduces to Morgan–Rubin complete rerandomization.
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The above methodology continues as follows. For the kth group of units, we randomize nk units to
treatment and nk units to control and denote the tentative assignment by W ∗k . It should be emphasized
that sequential rerandomization takes into account all the data and fixed assignments from the first k − 1
groups, namelyX1:(k−1) = (X1, · · · , Xk−1) andW1:(k−1) = (W>1 , . . . ,W>k−1)>, in addition to the data
from the kth group. The total number of subjects used to assess the acceptability of W ∗k for the kth group
is 2n1:k, where n1:k =
∑k
j=1 nj . The assignment of the first k groups using W
∗
k is denoted by
W ∗1:k =
(
W>1 , . . . ,W
>
k−1,W
∗
k
>
)>
,
which is a vector with 2n1:k components. The superscript ∗ on the right-hand side only occurs at the kth
term because the assignment vectors of the first k − 1 groups are already fixed. The mean vectors of the
first k treatment and control groups are written as
X¯∗T,1:k =
1
n1:k
X1:kW
∗
1:k, X¯
∗
C,1:k =
1
n1:k
X1:k(1−W ∗1:k),
with corresponding Mahalanobis distance for the first k groups
M∗k =
n1:k
2
(X¯∗T,1:k − X¯∗C,1:k)>cov(X1:k)−1(X¯∗T,1:k − X¯∗C,1:k), (1)
where cov(X1:k) is the sample covariance matrix of X1:k, which is assumed to be full rank. Given ak, we
decide whether W ∗k is acceptable by evaluating the pre-specified rerandomization criterion
ϕk(X1:k,W
∗
1:k) =
{
1 if M∗k < ak,
0 otherwise, (2)
where n1, . . . , nK must be sufficiently large in order to ensure that an acceptable randomization can be
realized. The threshold ak can be chosen as a function of M1, . . . ,Mk−1, but as we will see shortly
in Section 3·2, Mk−1 alone is sufficient for choosing ak. After the experimenter has concluded the se-
quential allocations, the Mahalanobis distance is calculated on the complete dataset X = X1:K using the
appropriate version of (1).
3. PROPERTIES OF SEQUENTIAL RERANDOMIZATION
3·1. Average treatment effect estimation
Now we present the key mathematical consequences for the sequential rerandomization framework
outlined in Section 2. We begin by the estimation for the true average treatment effect for the entire
sample. Suppose the potential outcome for unit i after treatment or control is yi(1) or yi(0), respectively,
according to the Rubin causal model (Rubin, 1974). Let the observed response Yi = yi(1) if Wi = 1 and
Yi = yi(0) otherwise. The average treatment effect is
τ =
∑2N
i=1 yi(1)−
∑2N
i=1 yi(0)
2N
.
The usual estimate of τ is the difference between treatment group and control group sample means:
τˆ = Y¯T − Y¯C = 1
N
2N∑
i=1
YiWi − 1
N
2N∑
i=1
Yi(1−Wi) = 1
N
Y >(2W − 1), (3)
where Y is the vector of the outcomes. As expected, τˆ is an unbiased estimator for τ .
PROPOSITION 1. For our sequential rerandomization, E (τˆ | X,ϕ1 = · · · = ϕK = 1) = τ.
Proof. See Appendix A·1. In fact, for τˆ to be unbiased, we only require the rerandomization criterion
satisfies ϕk(X1:k,W ∗1:k) = ϕk(X1:k, 1−W ∗1:k) for each k, and each group contains the same number of
treatment and control units. 
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Next consider the sampling variance of τˆ . Following the argument of Morgan & Rubin (2012), when
the treatment effect is an additive constant for all units, we decompose Yi as
Yi = βˆ0 + βˆ
>Xi + τWi + eˆi, i = 1, . . . , 2N, (4)
where βˆ0 + βˆ>Xi is the projection of yi(0) onto the space spanned by (1, X>), and eˆi is the projection of
yi(0) onto the orthogonal complement of that space. Letting e¯T and e¯C be the mean of eˆi for the treatment
and control groups respectively, by (3) and (4), we have
var(τˆ) = var
{
βˆ>(X¯T − X¯C) + e¯T − e¯C
}
= βˆ>cov(X¯T − X¯C)βˆ + var(e¯T − e¯C), (5)
where X¯T and X¯C are the covariate mean vectors of treatment and control groups. A natural line of
enquiry is to find the reduction in cov(X¯T − X¯C | X,ϕ1 = · · · = ϕk = 1) under sequential rerandom-
ization relative to cov(X¯T − X¯C | X) under complete randomization, which could be used to derive the
reduction in the variance of the estimation for τ . Recall that MK is the Mahalanobis distance of the entire
dataset after all sequential randomized allocations have been conducted.
THEOREM 1. Let ν = E(MK | X,ϕ1 = · · · = ϕK = 1)/p. We have
cov(X¯T − X¯C | X,ϕ1 = · · · = ϕK = 1) = νcov(X¯T − X¯C | X).
Proof. See Appendix A·2. 
THEOREM 2. Let τ˜ be the estimator for τ for complete randomization and τˆ be the estimator for τ for
sequential rerandomization. Assuming the treatment effect is additive, we have
var(τ˜)− var(τˆ)
var(τ˜)
= (1− ν)R2, (6)
where R2 is the squared multiple correlation between Y and X in either the treatment or control group.
Proof. See Appendix A·3. 
These results can be seen as extensions of those presented in Morgan & Rubin (2012). When K = 1,
the expression for ν reduces to eq. (9) in Morgan & Rubin (2012). Henceforth we shall simply write
E(Mk | X) instead of E(Mk | X,ϕ1 = · · · = ϕk = 1) since the notation Mk clearly implies that se-
quential rerandomization has been conducted.
3·2. Asymptotic minimization of the expected Mahalanobis distance
Theorem 1 proves that, under the additive treatment effect model, var(τˆ) is minimized when E(MK |
X) is minimized. In this section we shall propose an asymptotically optimal strategy that minimizes
E(MK | X) and thus makes the estimation of average treatment effect most precise. To this end, we first
seek the distribution ofMk, whose distribution is a truncated version of the distribution ofM∗k . Recall that
X1, . . . , XK are treated as fixed and the randomness only comes from the treatment/control assignment.
We further assume the data is homogeneous so that cov(Xk) ≈ cov(X1:k). The heterogeneous case will
be discussed in Section 5·1. By (1), the distribution of M∗k depends on the p-dimensional random variable
D∗k = X¯
∗
T,k − X¯∗C,k =
1
nk
XkW
∗
k −
1
nk
Xk(1−W ∗k ) = 2X¯∗T,k − 2X¯k. (7)
As shown below in Lemma 1, whenD∗k is normally distributed, the distribution ofM
∗
k is fully determined
by the value of Mk−1, which is a non-central chi-squared distribution with non-centrality parameter pro-
portional to Mk−1. Consequently, when choosing the threshold ak in (2), we only need to use Mk−1,
since conditional on Mk−1, M∗k is independent of M1, . . . ,Mk−2.
LEMMA 1. Assume D∗k | Xk ∼ N{0, 2n−1k cov(Xk)} and cov(Xk) ≈ cov(X1:k). Let Mk−1 be the
Mahalanobis distance for the first k − 1 treatment and control groups after rerandomization withM0 = 0,
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then
M∗k | Xk,Mk−1 ∼
nk
n1:k
χ2p
(
n1:k − nk
nk
Mk−1
)
, (8)
where χ2p(λ) denotes a non-central chi-squared distribution with p degrees of freedom and non-centrality
parameter λ.
Proof. See Appendix A·4. 
Remark 1. For sufficiently large n1, . . . , nK , the assumption that D∗k | Xk ∼ N{0, 2n−1k cov(Xk)}
holds under very general settings (Li & Ding, 2017). According to our sequential rerandomization pro-
cedure, the covariate mean of the kth treatment group, the term X¯∗T,k in (7), can be viewed as the mean
of samples from a finite population without replacement. Under certain regularity conditions, the lat-
ter is known to follow a normal distribution asymptotically (Wald & Wolfowitz, 1944). By Hoeffding
(1951) and Ha´jek (1961), a sufficient condition is as follows: the column vectors X1, . . . , X2N are i.i.d.
p-dimensional random vectors from a distribution with finite third absolute moments and with a positive
definite covariance matrix. Then as nk →∞,√nkD∗k converges in distribution toN{0, 2cov(Xk)}. This
result will be used to computeE(MK | X) and derive the optimal strategy for sequential rerandomization.
Recall the sequential rerandomization criteria ϕ1, . . . , ϕK defined in (2). We use the distribution given
in (8) to choose ak so that FM∗k (ak) = αk, where FM∗k is the conditional distribution function of M
∗
k
given Mk−1, and αk is the acceptance probability of each randomization. The number of randomizations
required for ϕk to evaluate to 1 is distributed as a geometric random variable with expectation sk = 1/αk.
Hence, if we know how to choose sk, we can choose ak accordingly by the distribution of M∗k given
in Lemma 1, and we denote this by writing ak = ak(Mk−1, sk). Equipped with modern computational
resources, it is reasonable to assume that the experimenter may perform rerandomization a very large
number of times. We may therefore assume that s1, . . . , sK are sufficiently large and that M1, . . . ,MK
are correspondingly small. Using an asymptotic result for truncated non-central chi-squared distribution
(Lemma 2 given below), we proceed to find an asymptotic expression for the expected value of Mk
conditional on Mk−1 in Lemma 3.
LEMMA 2. Let M be a random variable that follows χ2p(λ) and FM be its c.d.f. As a ↓ 0,
FM (a) ∼ a
p/2e−λ/2
2p/2Γ(p/2 + 1)
, E(M |M < a) ∼ pa
p+ 2
,
where ∼ denotes asymptotic equivalence: for two positive functions f(x) and g(x), we write f ∼ g as
x→ x0 if and only if limx→x0 f(x)/g(x) = 1.
Proof. See Appendix A·5. 
LEMMA 3. SupposeM∗k (k = 1, . . . ,K) follows the distribution given in Lemma 1 and pr(M
∗
k < ak |
Xk,Mk−1) = 1/sk. Then as sk ↑ ∞ and Mk−1 ↓ 0,
E(Mk | Xk,Mk−1) ∼ nk
n1:k
Cps
−2/p
k
(
1 +
n1:k − nk
pnk
Mk−1
)
,
where Cp = 2p{Γ(p/2 + 1)}2/p/(p+ 2).
Proof. See Appendix A·6. 
Let the expected total number of rerandomizations S = s1 + · · ·+ sK be sufficiently large. Proposition
2 details the asymptotically optimal strategy for choosing s1, . . . , sK , in which optimality is achieved by
asymptotically minimizing E(MK | X) for fixed S.
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PROPOSITION 2. Suppose M∗k (k = 1, . . . ,K) follows the distribution given in Lemma 1. As S ↑ ∞,
in order to minimize E(MK | X), one should choose s1, . . . , sK so that
sk−1 ≈
(
Cpnk−1
pnk
sk
)p/(p+2)
, Cp =
2p
p+ 2
Γ(p/2 + 1)2/p. (9)
Proof. See Appendix A·7. 
4. COMPARING SEQUENTIAL RERANDOMIZATION WITH MORGAN–RUBIN COMPLETE
RERANDOMIZATION
In this section, we compare sequential rerandomization with Morgan–Rubin complete rerandomization.
We begin by recalling the Morgan–Rubin complete rerandomization algorithm; 2N units are assumed to
be enrolled when the rerandomization starts and randomizations are conducted until the Mahalanobis
distance M∗ is smaller than some pre-specified threshold a, where
M∗ =
N
2
(X¯∗T − X¯∗C)>cov(X)−1(X¯∗T − X¯∗C). (10)
When the rerandomization stops, let M = M∗. Asymptotically, the distribution of M is a truncated chi-
squared distribution with support (0, a). This statistic M denotes the same quantity as the statistic MK in
sequential rerandomization; namely, it is the Mahalanobis distance calculated on the entire sample after
all units have received treatment assignment. If (in expectation) the same number of rerandomizations are
conducted in Morgan–Rubin complete rerandomization and sequential rerandomization, it is tempting to
conjecture that E(M | X), which we define as the expected Mahalanobis distance from Morgan–Rubin
complete rerandomization, should be smaller than E(MK | X), since Morgan–Rubin complete reran-
domization considers all (2N)!/N !N ! possible allocations, whereas sequential rerandomization selects
from a subset of those that are allowed by the sequential design. Surprisingly, as we will now prove in
Theorem 3 below, under certain asymptotic conditions, the opposite holds true.
THEOREM 3. Let n1, . . . , nK be given and S ∈ N be the expected total number of rerandomizations.
For Morgan–Rubin complete rerandomization, choose the threshold a such that pr(M∗ < a | X) = 1/S;
for sequential rerandomization, choose s1, . . . , sK according to Proposition 2 under the constraint∑K
i=1 si = S and then choose thresholds ak such that pr(M
∗
k < ak | Xk,Mk−1) = 1/sk. Then, assum-
ing M∗k given Mk−1 (k = 1, . . . ,K) follows the distribution given in Lemma 1, as S ↑ ∞,
E(MK | X) ∼ nK
N
E(M | X). (11)
Proof. See Appendix A·8. 
COROLLARY 1. Under the assumptions of Theorem 3 and assuming n1 = · · · = nK , as S grows to
infinity, E(MK | X) ∼ E(M | X)/K.
Remark 2. We pause to offer some intuition for Theorem 3. The rerandomization of the last group is
the most important step because any imbalance between the first K − 1 treatment and control groups
may be cancelled out, making the entire dataset balanced once again. Heuristically, an efficient sequential
rerandomization strategy need only ensure that the imbalance accumulated in the first K − 1 groups is
sufficiently small and then perform most rerandomizations for the last group. In fact, any strategy that
satisfies the following two conditions would make Theorem 3 hold: (i) as S ↑ ∞, every sk does so too;
(ii) S ∼ sK . The first condition ensures everyMk will decrease to zero and thus, by Lemma 1,Nn−1K M∗K
converges to a χ2p random variable. The second condition guarantees that, asymptotically, Nn
−1
K MK and
M are equivalent (in expectation) because they are truncated at the same threshold.
The consequences of the results in this section can be significant for clinical trials research. If a large
number of individuals are enrolled simultaneously, Theorem 3 says that it is advantageous to use sequen-
tial rerandomization in lieu of Morgan–Rubin complete rerandomization. In Appendix B, we conduct
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multiple simulation studies using both simulated and real datasets to show that sequential rerandomiza-
tion achieves smaller Mahalanobis distance in almost every practical setting.
5. DISCUSSION
5·1. Generalizations of our results
In practice, experimenters may prefer unequal allocation schemes where the numbers of treatment and
control units are not equal (Hey & Kimmelman, 2014). Let ω be the proportion of treatment assignments.
If ω is a constant across all the groups, as long as we use the correct version of Mahalanobis distance
(see eq. (A8) in Appendix A·9), all our results still hold. More generally, our results can be extended to a
heterogeneous dataset where cov(Xk) is very different across the groups. This happens when the clinical
trial has a large time span or the groups of samples are collected at different places. The key is to find an
appropriate form of Mahalanobis distance. In Appendix A·9, we propose to standardize the data separately
for each group and then compute the Mahalanobis distance using the standardized variables with proper
weights (see eq. (A7)). It can be viewed as a generalization of the Mahalanobis distance defined in (1)
and a corresponding generalized version of Lemma 1 is also proved (see Lemma A1). Since Lemma 1
characterizes the conditional distribution of M∗k and is the foundation of all the subsequent results, our
main results, Proposition 2 and Theorem 3, follow by the same argument.
When the data is heterogeneous, minimizing the overall imbalance may not be sufficient and thus
the strategy given in Proposition 2 becomes undesirable. For example, the effects of the covariates may
change between the groups, and each group may have a unique systematic effect on the outcome. In
such cases, one may want to achieve good balance within each group and choose a more uniform value
for (s1, . . . , sK). We point out that, in terms of within-group balance, sequential rerandomization is still
superior to Morgan–Rubin complete rerandomization (see Appendix A·10 for details). Heuristically, this
is because even if we let the threshold a of Morgan-Rubin complete rerandomization go to zero, we are
only enforcing the within-group imbalances to cancel out but their absolute values can be arbitrarily large.
5·2. Towards an optimal procedure
For classical dynamic randomization procedures, it is often assumed that the assignment of a unit must
be determined as soon as he/she is enrolled. The seminal work of Atkinson (1982) proposes a type of
Efron’s biased coin procedure (Efron, 1971) that achieves optimum performance when the underlying
model is linear (see also Smith, 1984). A natural line of enquiry is to find the optimal procedure if the
participants arrive in groups and the rerandomization technique is employed. Such questions have to be
formulated very carefully. Even if all the participants arrive at one time, the deterministic construction that
minimizes the Mahalanobis distance is usually undesirable for the following two reasons. Firstly, for large
sample sizes, the construction is not practical since finding the deterministic optimum is a non-convex op-
timization problem. Secondly, we want the procedure to possess certain degree of randomness to avoid
the selection bias (Antognini & Zagoraiou, 2017). Qin et al. (2016) introduces a procedure which can
be applied when the participants arrive in pairs. For the kth pair, they consider the two 1:1 assignment
schemes and choose the one that gives a smaller Mahalanobis distance of the first 2k units with proba-
bility q ∈ (1/2, 1). In Appendix B·3, we apply this procedure to a real dataset. When q = 0.75 (the value
suggested in their work), the Mahalanobis distance of the entire dataset is only sightly smaller than that
of Morgan–Rubin complete rerandomization, but is greater than those of our sequential designs. For com-
parison, when q = 1, which makes the whole procedure deterministic, the Mahalanobis distance reduces
dramatically. We believe that when the group size of a sequential design is small, the covariate imbalance
can only be efficiently minimized at the cost of selection bias, i.e. the procedure being more deterministic.
Kapelner & Krieger (2014) offers a more complicated dynamic procedure which also uses Mahalanobis
distance, but some participants may wait a long time before being assigned. We believe, in order to find
an optimal procedure, one needs to strike a balance between the following factors: covariate imbalance
(measured by Mahalanobis distance), group size of the sequential enrollment design, and the randomness
and computational cost of the procedure.
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Supplementary Material
APPENDIX A: PROOFS
A·1. Proof for Proposition 1
Proof. The proof is essentially the same as the proof for Theorem 2.1 in Morgan & Rubin (2012). For a
standard completely randomized trial, W and 1−W have the same probability distributions. For sequen-
tial rerandomization, if ϕk(X1:k,W ∗1:k) = ϕk(X1:k, 1−W ∗1:k) for every k, the conditional probabilities
pr(W1:k | ϕ1 = · · · = ϕK = 1) and pr(1−W1:k | ϕ1 = · · · = ϕK = 1)
are equal by symmetry. Therefore,
E(Wi | X,ϕ1 = · · · = ϕK = 1) = E(1−Wi | X,ϕ1 = · · · = ϕK = 1) = 1
2
.
This gives
E(τˆ | X,ϕ1 = · · · = ϕk = 1)
=
1
N
E
{
2N∑
i=1
WiYi −
2N∑
i=1
(1−Wi)Yi | X,ϕ1 = · · · = ϕK = 1
}
=
1
N
E
{
2N∑
i=1
Wiyi(1)−
2N∑
i=1
(1−Wi)yi(0) | X,ϕ1 = · · · = ϕK = 1
}
=
1
2N
2N∑
i=1
{yi(1)− yi(0)} = τ.
The proposition is thus proved. 
A·2. Proof for Theorem 1
Proof. The proof is similar to the proof for Theorem 3.1 in Morgan & Rubin (2012). Let cov(X) be
the sample covariance matrix, which is defined as
{cov(X)}ij =
1
2N − 1
2N∑
k=1
(Xik − X¯i)(Xjk − X¯j), i, j ∈ {1, . . . , p}.
Because X¯T − X¯C = 2(X¯T − X¯), where X¯ is the overall mean vector of X (which is fixed),
cov(X¯T − X¯C | X) = 4cov(X¯T | X) = 2N−1cov(X). (A1)
Note that X¯T is the sample mean of a random subsample without replacement of sizeN from a population
of size 2N . Hence, the second equality can be derived by applying eq. (2.9) of Sen (1995). Let
Z = (N/2)1/2cov(X)−1/2(X¯T − X¯C).
ThusE(Z | X) = 0 and cov(Z | X) = I . For sequential rerandomization, we may decompose X¯T − X¯C
into a weighted sum of X¯T,i − X¯C,i, where the weights are given by ni/N , i.e.,
X¯T − X¯C = 1
N
K∑
i=1
ni
(
X¯T,i − X¯C,i
)
.
Accordingly, Z can be decomposed as the sum of K components, Z(1), . . . , Z(K), defined by
Z(i) =
ni
N
(N/2)1/2cov(X)−1/2(X¯T,i − X¯C,i).
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Given ϕ1 = · · · = ϕK = 1, by (1), Z>Z = MK . Furthermore, if we exchange (Z(1)i , . . . , Z(K)i ) with
(Z
(1)
j , . . . , Z
(K)
j ), one can check that the Mahalanobis distances M1, . . . ,MK remain the same, which
implies that Z1, . . . , Zp (the row vectors of Z) are exchangeable conditioning on M1, . . . ,Mk. Therefore,
var(Zi | X,ϕ1 = · · · = ϕK = 1) = E(Z>Z | X,ϕ1 = · · · = ϕK = 1)/p
= E(MK | X,ϕ1 = · · · = ϕK = 1)/p.
By the property of the Mahalanobis distance, if the sign of one covariate is interchanged (e.g., Zi to−Zi),
ϕ1, . . . , ϕk will be unchanged. By this symmetry,
cov(Zi, Zj | X,ϕ1 = · · · = ϕK = 1) = E(ZiZj | X,ϕ1 = · · · = ϕK = 1)
= cov(−Zi, Zj | X,ϕ1 = · · · = ϕK = 1) = E(−ZiZj | X,ϕ1 = · · · = ϕK = 1),
which implies
cov(Zi, Zj | X,ϕ1 = · · · = ϕK = 1) = 0.
Therefore, using X¯T − X¯C = (2/N)1/2cov(X)1/2Z, we obtain
cov(X¯T − X¯C | X,ϕ1 = · · · = ϕK = 1) = 2E(MK | X,ϕ1 = · · · = ϕK = 1)cov(X)/Np.
Since cov(X¯T − X¯C | X) = 2cov(X)/N , the theorem follows. 
A·3. Proof for Theorem 2
Proof. The proof is essentially the same as the proof for Theorem 3.2 in Morgan & Rubin (2012). By
Theorem 1 and (5) and assuming the normality of the mean vectors X¯T , X¯C , e¯T , e¯C (so that orthogonality
implies independence),
var(τ˜) = βˆ>cov(X¯T − X¯C | X)βˆ + var(e¯T − e¯C | X),
var(τˆ) = βˆ>cov(X¯T − X¯C | X,ϕ1 = · · · = ϕk = 1)βˆ + var(e¯T − e¯C | X,ϕ1 = · · · = ϕk = 1)
= νβˆ>cov(X¯T − X¯C | X)βˆ + var(e¯T − e¯C | X).
Recall by (A1) that cov(X¯T − X¯C | X) = 2cov(X)/N . Let σ2e be the variance of eˆ1, . . . , eˆ2N . Using the
same argument we can show that var(e¯T − e¯C | X) = 2σ2e/N . Hence,
var(τ˜)− var(τˆ)
var(τ˜)
=
(1− ν)var(X>βˆ)
var(X>βˆ) + σ2e
= (1− ν)R2,
which proves the theorem. 
A·4. Proof for Lemma 1
Proof. Define D∗1:k = X¯
∗
T,1:k − X¯∗C,1:k. During the rerandomization of the kth group, D∗1:k may be
decomposed as a weighted average of the constant D1:(k−1) (which has already been fixed in the reran-
domization of the last group) and the random variable D∗k by
D∗1:k =
n1:(k−1)
n1:k
D1:(k−1) +
nk
n1:k
D∗k. (A2)
Since D∗k | Xk ∼ N{0, 2n−1k cov(Xk)} by assumption,
D∗1:k | Xk, D1:(k−1) ∼ N
{
n1:(k−1)
n1:k
D1:(k−1),
2nk
n21:k
cov(Xk)
}
.
Hence,
√
n1:k√
nk
√
n1:k√
2
{cov(Xk)}−1/2D∗1:k | Xk, D1:(k−1) ∼ N
{
n1:(k−1)√
2nk
{cov(Xk)}−1/2D1:(k−1), I
}
.
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The squared `2-norm of this random vector follows a non-central chi-squared distribution,
n1:k
nk
(n1:k
2
D∗>1:k {cov(Xk)}−1D∗1:k
)
| Xk, D1:(k−1)
∼ χ2p
(
n1:(k−1)
nk
n1:(k−1)
2
D>1:(k−1) {cov(Xk)}−1D1:(k−1)
)
.
Since we assume the samples are homogeneous so that cov(Xk) ≈ cov(X1:k−1) ≈ cov(X1:k), by the
definition of M∗k given in (1), the left-hand side of the above equation is equal to n1:kM
∗
k/nk; the non-
centrality parameter on the right-hand side is equal to n1:(k−1)Mk−1/nk (note thatMk−1 has already been
fixed). The Lemma is then verified by noting that conditioning on D1:(k−1) is equivalent to conditioning
on Mk−1. 
A·5. Proof for Lemma 2
Proof. We refer the reader to Richter & Schumacher (2000) for more general results. Herein we offer a
simple proof. Let Fχ2p and fχ2p be the c.d.f. and p.d.f. of (central) χ
2
p distribution respectively. We have
Fχ2p(a) ∼
ap/2
2p/2Γ(p/2 + 1)
, as a ↓ 0. (A3)
To prove this, note that by L’Hoˆpital’s rule,
lim
a↓0
Fχ2p(a)
ap/2/2p/2Γ(p/2 + 1)
= lim
a↓0
fχ2p(a)
ap/2−1/2p/2Γ(p/2)
= 1.
The c.d.f. of a non-central chi-squared distribution can be written as (Sankaran, 1963)
FM (a) =
∞∑
k=0
e−λ/2(λ/2)k
k!
Fχ2p+2k(a). (A4)
Using (A3), we obtain
FM (a) ∼ a
p/2
2p/2
∞∑
k=0
e−λ/2(λa/4)k
k! Γ(p/2 + k + 1)
∼ a
p/2e−λ/2
2p/2Γ(p/2 + 1)
as a decreases to zero. Similarly, using L’Hoˆpital’s rule one can verify that∫ a
0
ydFχ2p(y) ∼
2ap/2+1
(p+ 2)2p/2Γ(p/2)
, as a ↓ 0.
Then for the non-central chi-squared distribution, using (A4) we obtain∫ a
0
ydFM (y) ∼ 2a
p/2+1e−λ/2
(p+ 2)2p/2 Γ(p/2)
, as a ↓ 0,
which leads to E(M |M < a) = ∫ a
0
ydFM (y)/FM (a) ∼ pa/(p+ 2). 
A·6. Proof for Lemma 3
Proof. Define qk = n1:k/nk. By Lemma 1,
qkM
∗
k | Xk,Mk−1 ∼ χ2p {(qk − 1)Mk−1} .
By Lemma 2, if pr(qkM∗k < qkak | Xk,Mk−1) = 1/sk, we have
1/sk ∼ (qkak)
p/2 exp {−(qk − 1)Mk−1/2}
2p/2Γ(p/2 + 1)
, as sk ↑ ∞
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which after rearrangement yields
qkak ∼
{
s−1k exp
(
qk − 1
2
Mk−1
)
2p/2Γ(p/2 + 1)
}2/p
, as sk ↑ ∞.
Employing the facts that ex ∼ 1 + x and (1 + x)c ∼ 1 + cx as x ↓ 0, we obtain
E(qkM
∗
k | qkM∗k < qkak, Xk,Mk−1) ∼
2p
p+ 2
{
s−1k exp
(
qk − 1
2
Mk−1
)
Γ(p/2 + 1)
}2/p
∼ 2p
p+ 2
{
s−1k Γ(p/2 + 1)
}2/p(
1 +
qk − 1
p
Mk−1
)
.
By definition, E(M∗k |M∗k < ak, Xk,Mk−1) = E(Mk | Xk,Mk−1) and the result now follows. 
A·7. Proof for Proposition 2
Proof. We first make two observations about the given strategy. Firstly, as the expected total num-
ber of rerandomizations, S = s1 + · · ·+ sK , goes to infinity, for every k, sk ↑ ∞ (this can be easily
proven by contradiction). Secondly, since p/(p+ 2) < 1, we have sk−1 = o(sk) as sk goes to infinity, i.e.
limsk↑∞ sk−1/sk = 0, for k = 2, . . . ,K, which further implies that s1 + · · ·+ sk ∼ sk, and in particular,
sK ∼ S.
By Lemma 1 and by the definition of s1, a1 = F−1χ2p (1/s1) ≥M1. Thus we haveM1 = o(1) as s1 ↑ ∞.
(note that we do not need to write M1 = op(1) since M1 ∈ [0, a1].) Similarly, a2 is the s−12 -quantile
of a scaled non-central chi-squared distribution with non-centrality parameter approaching 0. Hence as
s2 ↑ ∞, a2 = o(1) and so does M2. Using this argument iteratively, we obtain Mk = o(1) for every k.
Hence the condition of Lemma 3 is satisfied for every k. Applying Lemma 3 twice, we obtain
E(MK | X,MK−2) = E {E(MK | Xk,MK−1) | Xk−1,MK−2}
∼ E
{
nK
N
Cps
−2/p
K
(
1 +
N − nk
pnK
MK−1
)
| Xk−1,MK−2
}
∼ nK
N
Cps
−2/p
K
{
1 +
nK−1
pnK
Cps
−2/p
K−1
(
1 +
n1:(K−2)
pnK−1
MK−2
)}
∼ nK
N
Cps
−2/p
K
{
1 +
nK−1
pnK
Cps
−2/p
K−1
}
= g.
(A5)
Note that in the final step we omitted the term involving MK−2 because it is o(1). Now consider given
W1:(K−2), s1, . . . , sK−2, and MK−2, how one might choose the expected number of rerandomizations
of the last two groups, i.e. sK−1 and sK , to minimize E(Mk |MK−2). Let sK + sK−1 = S˜. We can
differentiate the function g defined in (A5) with respect to sK−1 as follows
∂g
∂sK−1
∝ (S˜ − sK−1)−(p+2)/p
{
CpnK−1
pnK
s
−2/p
K−1
(
S˜
sK−1
− 2
)
− 1
}
.
Because sK−1 = o(sK) as sK ↑ ∞ for the strategy given in (9), we have S˜/sK−1 − 2 ∼ S˜/sK−1, and
∂g
∂sK−1
∼ (S˜ − sK−1)−(p+2)/p
(
CpnK−1
pnK
S˜/s
(p+2)/p
K−1 − 1
)
.
The right-hand side is 0 if
sK−1 =
(
CpnK−1
pnK
S˜
)p/(p+2)
∼
(
CpnK−1
pnK
sK
)p/(p+2)
, as S˜ ↑ ∞.
The second asymptotic equality follows from the fact that sK−1 + sK ∼ sK for the given strategy. The
same argument then can be iteratively applied to find sK−2, . . . , s1. 
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A·8. Proof for Theorem 3
Proof. According to the strategy given in Proposition 2, as S goes to infinity, we have, for every k,
sk ↑ ∞ and thus Mk ↓ 0. Hence by Lemma 3,
E(MK | X) ∼ nK
N
Cps
−2/p
K .
Since Morgan–Rubin complete rerandomization is equivalent to sequential rerandomization with only
one group, E(M | X) ∼ CpS−2/p. But by the optimal strategy of Proposition 2 we also have sK ∼ S as
S ↑ ∞. The conclusion thus follows. 
A·9. Extension of Lemma 1 to general sequential studies
Our results are applicable to very general sequential designs in which unequal allocation schemes are
permitted and in which data is heterogeneous across the groups. Suppose that for the kth group, there are
2nk units enrolled and we assign ω(2nk) units to the treatment and (1− ω)(2nk) units to the control.
The sample covariance matrix cov(Xk) may be very different for different groups. To find an appropriate
expression for the Mahalanobis distance, we need to first compute the covariance matrix ofD∗k = X¯
∗
T,k −
X¯∗C,k. Using the variance formula for the sample mean of a random subsample without replacement from
a finite population (recall (A1)), it is straightforward to show that
cov(D∗k | Xk) =
1
2nkω(1− ω)cov(Xk).
Define the standardized covariate difference vector Z∗k by
Z∗k = {2nkω(1− ω)}1/2 {cov(Xk)}−1/2 (X¯∗T,k − X¯∗C,k). (A6)
The Mahalanobis distance between the kth treatment and control groups is given as (Z∗k)
>Z∗k . Recall that
when we conduct the rerandomization of the kth group, the assignments of the first k − 1 groups have
already been fixed. Therefore, when we generate a random assignment for the kth group, we may compute
M∗k (the Mahalanobis distance for the first k groups) as
M∗k =
1
n1:k
(√
n1Z1 + · · ·+√nk−1Zk−1 +√nkZ∗k
)> (√
n1Z1 + · · ·+√nk−1Zk−1 +√nkZ∗k
)
,
(A7)
where Z1, . . . , Zk−1 are the corresponding realized values for the first k − 1 groups. It is straightforward
to check that when cov(Xk) is approximately the same for every k, this expression for M∗k reduces
to (Morgan & Rubin, 2012; Qin et al., 2016)
M∗k = 2n1:kω(1− ω)(X¯∗T,1:k − X¯∗C,1:k)> {cov(X1:k)}−1 (X¯∗T,1:k − X¯∗C,1:k). (A8)
If ω = 1/2, (A8) further reduces to (1). Recall that by Remark 1, as nk ↑ ∞, Z∗k asymptotically follows a
standard multivariate normal distribution. We now prove a generalized version of Lemma 1.
LEMMA A1 (EXTENSION OF LEMMA 1). Assume that Z∗k | Xk ∼ N (0, I) where Z∗k is defined
in (A6). Then, for the Mahalanobis distance M∗k given in (A7), we have
M∗k | Xk,Mk−1 ∼
nk
n1:k
χ2p
(
n1:k − nk
nk
Mk−1
)
,
where Mk−1 is the realized value of the Mahalanobis distance of the first k − 1 groups.
Proof. By (A7),
n1:k
nk
M∗k =
(√
n1
nk
Z1 + · · ·+
√
nk−1
nk
Zk−1 + Z∗k
)>(√
n1
nk
Z1 + · · ·+
√
nk−1
nk
Zk−1 + Z∗k
)
.
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The right-hand side is a non-central chi-squared random variable with p degrees of freedom and non-
centrality parameter(√
n1
nk
Z1 + · · ·+
√
nk−1
nk
Zk−1
)>(√
n1
nk
Z1 + · · ·+
√
nk−1
nk
Zk−1
)
=
n1:(k−1)
nk
Mk−1.
The lemma then follows. 
A·10. Lemma A2 and its proof
LEMMA A2. Let Y1, Y2 be two independent standard normal variables. For two positive constants
α1, α2, we have
E(Y 21 | (α1Y1 + α2Y2)2 < c) = 1−
2βγφ(γ)
Φ(γ)− Φ(−γ) , (A9)
where
β =
α21
α21 + α
2
2
, γ =
√
c
α21 + α
2
2
.
Consequently,
lim
c↓0
E
{
Y 21 | (α1Y1 + α2Y2)2 < c
}
= 1− β.
Proof. We compute E(Y 21 I{(α1Y1+α2Y2)2<c}), which is equal to∫ ∞
−∞
x2φ(x)
{
Φ
(√
c− α1x
α2
)
− Φ
(−√c− α1x
α2
)}
dx,
where φ(x),Φ(x) are the p.d.f. and c.d.f. of the standard normal distribution respectively. Heavy calcula-
tion shows that the above display can be reexpressed as
Φ(γ)− Φ(−γ)− 2βγφ(γ).
Since α1Y1 + α2Y2 is a normal variable with mean 0 and variance α21 + α
2
2,
pr{(α1Y1 + α2Y2)2 < c} = Φ(γ)− Φ(−γ).
Eq. (A9) then follows. The limit as c decreases to 0 can be computed by applying L’Hoˆpital’s rule. 
Remark A1. Consider the sequential rerandomization procedure in the simplest setting p = 1 and K =
2. As shown in (A7), the Mahalanbois distances can be expressed as
M1 = Z
2
1 , M2 = N
−1(
√
n1Z1 +
√
n2Z2)
2,
where the corresponding proposed value Z∗k (defined in (A6)) asymptotically follows a standard normal
distribution. When we rerandomize the first group, we are proposing Z∗1 and we stop when M
∗
1 < a1.
Then given the value of M1, we proceed to the second group and propose values for Z∗2 .
On the other hand, assuming the first 2n1 units are equally allocated to treatment and control, for
Morgan-Rubin complete rerandomization, we may write
M = N−1(
√
n1Z1 +
√
n2Z2)
2.
Morgan-Rubin complete rerandomization proposes Z∗1 and Z
∗
2 simultaneously and stops if
N−1(
√
n1Z
∗
1 +
√
n2Z
∗
2 )
2 < a. By Lemma A2, when Morgan-Rubin complete rerandomization is con-
ducted, we have Z21 → n2/N as a ↓ 0. That is, no matter how small the threshold a, we have no guarantee
for the balance of the first 2n1 units. In fact, conducting a few rerandomizations using only the first 2n1
units would be superior. For example, if n1 = n2, we have Z21 → 1/2 as a ↓ 0. This is not surprising since
as long as for both groups we perform a 1:1 assignment to treatment and control, the overall difference,
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X¯T − X¯C , will be the average of two within-group differences. As we let the threshold a of Morgan-
Rubin complete rerandomization go to zero, we are only enforcing the two within-group quantities to
cancel out but their absolute values may still indeed be very large. However, for sequential rerandomiza-
tion, since Z∗1 follows χ
2
1, on average we only need less than three tries for the first group to achieve a
smaller value of M1. The same reasoning can be applied to the general case.
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APPENDIX B: SIMULATION STUDIES
Our simulation studies contain three parts. In the first, we consider ideal datasets such that Lemma 1
holds exactly; that is, D∗k (defined in (7)) is exactly normally distributed. Then by Lemma 1, the distribu-
tion ofMk is independent ofX and thus we shall simply writeE(MK) andE(M) instead ofE(MK | X)
and E(M | X). We employ Monte Carlo sampling to compare E(MK) with E(M) for different values
of K (the number of sample groups), p (the number of covariates) and S (the expected total number of
rerandomizations). From Theorem 3, we only know the ratio E(M)/E(MK) for S ↑ ∞, but it is not
clear whether sequential rerandomization is better for moderate S as well as how quickly E(M)/E(MK)
converges to N/nK . These problems are investigated in Section B·1.
Lemma 1 assumes D∗k is normally distributed for k = 1, . . . ,K. When this CLT-based approximation
is less accurate, either because the sample sizes are small or the distribution of X has heavy tails, there
are fewer advantages of sequential rerandomization relative to Morgan–Rubin complete rerandomization
(implied by Theorem 3). Hence we simulate X with different sample sizes and different distributions
in Section B·2 and compare the Mahalanobis distances after rerandomization from these datasets with
those of the ideal datasets. The results confirm that the conclusions from the first simulation study are
still applicable, although in some extreme cases, the advantage of sequential rerandomization becomes
weaker.
Section B·3 uses a real clinical dataset with a mixture of binary and continuous covariates (p = 12).
The results are consistent with those obtained for ideal datasets. We also use this dataset to study the effect
of choosing different values of (n1, . . . , nK). In all the designs considered, sequential rerandomization
performs best. Lastly, we apply the dynamic randomization method of Qin et al. (2016) to this dataset.
We now detail how s1, . . . , sK are computed for the simulation studies. In principle, we follow the
rule specified by Proposition 2: for some given S, we try to find a vector (s1, . . . , sK) such that the sum
is exactly equal to S, and approximately, sk−1 ≈ (Cpnk−1sk/pnk)p/(p+2). However, by this rule, sk
decreases exponentially as k varies from K to 1. Thus, for the first one or for the first few groups, the
value of sk that is computed according to this rule can be very small, which may greatly compromise the
efficiency of sequential rerandomization. Thus, for a given S, we set a lower bound for s1, . . . , sK . The
value for this lower bound is somewhat arbitrary; for example, for S ≥ 2000, we let the bound be 10. For
each simulation study, the value of (s1, . . . , sK) we use will be explicitly provided.
B·1. Study I: ideal datasets
For the first simulation study, we assume that n1 = · · · = nK as well as that the dataset is ideal
so that Lemma 1 holds exactly. We choose p = 2, 5, 10, K = 3, 5, 10, and let S range from 10 to
10, 000 (since S is finite, the theoretical guarantee of optimality under Proposition 2 is no longer ap-
plicable). For every combination of p and S, we compute the threshold a for Morgan–Rubin complete
rerandomization by a = F−1χ2p (1/S) and the expected Mahalanobis distance after rerandomization by
E(M) = p · S · Fχ2p+2(a). For sequential rerandomization, given p,K, S and n1 = · · · = nK , we com-
pute s1, . . . , sK by Proposition 2 and we calculate the thresholds a1, . . . , aK by Lemma 1. Then, using
Lemma 1, we sample (M1, . . . ,MK) 100, 000 times (directly from non-central chi-squared distributions)
and estimate E(MK) by the sample average for MK .
The results are displayed in Figure B1. Our first key observation is thatE(M) is greater thanE(MK) in
every case except when S is extremely small; for example, S = 10 forK = 5 and S = 10, 20 forK = 10.
As S increases, the ratio E(M)/E(MK) increases as well and eventually approaches the limit K. Next,
for each K, the convergence of E(M)/E(MK) to K is faster for smaller p. The main reason for this
behavior is that, by Lemma 3, given sufficiently small Mk−1, the expected value of Mk is O(s
−2/p
k ). This
behavior ofMk also affects how we allocate s1, . . . , sK ; recall that by Proposition 2, sk−1 = O(s
p/(p+2)
k ).
As a result, for larger p, S is more evenly allocated across the groups and thus sK becomes smaller. Under
this simulation setting, the parameter K does not have a significant impact on the convergence rate of
E(M)/E(MK), especially for p = 2. However, for a real fixed dataset, a largerK implies smaller sample
size of each group, and thus E(M)/E(MK) cannot keep growing as K grows.
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Fig. B1: This figure shows how the Mahalanobis distances change with increasing values of S, assuming
that Lemma 1 holds and that n1 = · · · = nK . The first row of panels gives the numerical values of E(M)
and E(MK) and the second row of panels display the ratio E(M)/E(MK). E(MK) is the average of
100, 000 Monte Carlo samples (in all cases, SE/Mean ≤ 0.003) and E(M) is computed exactly. See
Table B3 for the values of s1, . . . , sK .
B·2. Study II: simulated datasets
The first simulation study directly uses Lemma 1, but whether or not this lemma holds for a given
dataset depends on the sample size as well as on the distribution of X . For the second simulation study,
we fixK = 5, p = 5, S = 2000 and n1 = · · · = nK but simulate datasets with 2nk = 20, 50, 100. For the
distribution of X , we assume every entry Xij is an i.i.d. sample from some distribution G and consider
five choices for the distribution G: the standard normal distribution, the exponential distribution, the chi-
squared distribution with one degree of freedom, the Weibull distribution with shape parameter 0.6, and
the log-normal distribution (exponential of a standard normal variable). These five distributions have an
increasing excess kurtosis (the standardized fourth central moment minus three; see Table B1), which
measures the tailedness; the Weibull and log-normal distributions are common examples of heavy-tailed
distributions. Because all these distributions have finite absolute third moments, an ideal dataset in which
Lemma 1 holds exactly can always be obtained by letting N ↑ ∞ (see the last three rows of Table B1).
For every combination of 2nk and G, we perform 20, 000 Monte Carlo simulations and the data matrix
X is resampled each time. Therefore, we shall still write E(MK) and E(M) instead of E(MK | X) and
E(M | X). It should be noted that for a simulated dataset, it is likely that ϕk may never evaluate to 1,
especially whenX is heavy-tailed. Hence, for the rerandomization of the kth group, we only allow at most
10sk rerandomizations and use the best assignment, i.e., the one with minimum Mahalanobis distance, if
all rerandomizations fail to satisfy ϕk = 1.
The results are summarized in Table B1. For each choice of 2nk, the ratio E(M)/E(MK) is larger
when the distribution of X has a smaller kurtosis. For an ideal dataset (or equivalently 2nk =∞), we
have E(M)/E(MK) = 4.42, which is also obtained by the normal, exponential, and chi-squared distri-
butions for G when 2nk ≥ 50. If X is normally distributed, 2nk = 20 is already sufficiently large. For
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Table B1: E(M) and E(MK) for different simulated datasets
Distribution of X N (0, 1) Exp χ21 Weibull(0.6) exp(N (0, 1))
Excess kurtosis 0 6 12 37.5 111
E(M) 0.112 0.112 0.112 0.113 0.113
2nk = 100 E(MK) 0.0254 0.0255 0.0255 0.0258 0.0278
E(M)/E(MK) 4.42 4.40 4.42 4.36 4.06
E(M) 0.112 0.113 0.112 0.113 0.113
2nk = 50 E(MK) 0.0255 0.0256 0.0255 0.0284 0.0331
E(M)/E(MK) 4.41 4.40 4.41 3.97 3.42
E(M) 0.113 0.113 0.112 0.114 0.118
2nk = 20 E(MK) 0.0255 0.0269 0.0324 0.0602 0.0626
E(M)/E(MK) 4.42 4.18 3.46 1.89 1.89
E(M) 0.112
2nk =∞ E(MK) 0.0254
E(M)/E(MK) 4.42
For all datasets, we always use K = 5, p = 5 and S = 2000. “2nk =∞” refers to the Monte Carlo experiments using Lemma 1
(see also Figure B1). As indicated in Table B3, we use s1 = 10, s2 = 12, s3 = 22, s4 = 120, s5 = 1836. All the other estimates
of E(MK) and E(M) are obtained from 20, 000 Monte Carlo simulations. The estimates of E(M) have SE/Mean < 0.003 and
the estimates of E(MK) have SE/Mean < 0.01. For each distribution, the excess kurtosis is computed exactly.
the two heavy-tailed distributions (the Weibull and log-normal distributions), the finite-sample behavior
of sequential rerandomization is clearly worse than that under 2nk =∞. Note that 2nk = 100 still ap-
pears to be sufficient for the Weibull(0.6) distribution, but not for log-normal distribution, which has the
greatest kurtosis among the five distributions.
The distribution of X is often not of much practical concern. If X is distributed such that Lemma 1
does not hold, setting the thresholds ak based on Lemma 1 is likely to fail for large S. For example, in
our study for 2nk = 20 with X generated from a Weibull(0.6) distribution, only 41% of the Monte Carlo
simulations achieve ϕk = 1 for k = 1, . . . ,K and the mean ofMK of these samples is 0.0263. In practice,
when ϕk fails to evaluate to 1, or if we can visually detect a heavy tail of the empirical distribution of
some covariate, we should transform the data.
It is important to note that we did not consider discrete distributions such as the Bernoulli distribution.
This is because if all covariates are binary, we would need a much larger sample size for Lemma 1 to hold.
Consider the number of possible values of D∗k given nk. For continuous covariates, this number grows
super-exponentially with nk; if all covariates are binary, it only grows linearly with nk and thus converges
much more slowly to a normal distribution. The next simulation study with real dataset shows that as long
as a dataset has some continuous covariates, sequential rerandomization performs well.
B·3. Study III: TCGA-UCEC dataset
For the last simulation study, we utilize the clinical data of TCGA-UCEC project (TCGA Research
Network, 2013; Erickson et al., 2016) (TCGA: The Cancer Genome Atlas; UCEC: Uterine Corpus En-
dometrial Carcinoma), publicly available at NCI Genomic Data Commons (Grossman et al., 2016) and
The Cancer Imaging Archive (Clark et al., 2013). The dataset contains the clinical and demographic in-
formation of 548 UCEC cases. From the original data, we choose twelve covariates that have few missing
values and which are regarded as likely to be associated with the severity of tumor symptoms (more de-
tails are given in Appendix C). For each covariate, the missing values are imputed by sampling from the
observed values. Four covariates are continuous but only one is bell-shaped. Eight covariates are cate-
gorical and those with more than two levels are dichotomized, since otherwise the Mahalanobis distance
is not practically meaningful (even though some of these covariates appear to be ordinal, it is still very
difficult to attach sensible numerical values to more than two levels). After dichotomization, two of the
eight binary variables have the frequency of minor values less than .1 (we do not perform any transforma-
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tion). Histograms for all covariates are given in Appendix C (see Figure C1). We consider five sequential
enrollment designs:
(i) K = 1 and 2n1 = 548 (Morgan–Rubin complete rerandomization);
(ii) K = 3 and 2n1 = 184, 2n2 = 2n3 = 182;
(iii) K = 3 and 2n1 = 2n2 = 220, 2n3 = 108;
(iv) K = 5 and 2n1 = · · · = 2n4 = 110, 2n5 = 108;
(v) K = 10 and 2n1 = · · · = 2n4 = 56, 2n5 = · · · = 2n10 = 54.
For each design, we use S = 2000 and perform 20, 000 Monte Carlo simulations to obtain the sample
averages for the expected Mahalanobis distance after rerandomization. The entire data matrix is the same
across all the repeats, but for each repeat, we resample the group labels of all the individuals (i.e. the arrival
order of the individuals is resampled every time). For this reason, we still use the notation E(MK) and
E(M) instead of E(MK | X) and E(M | X). As in the second simulation study, for the rerandomization
of the kth group, we allow at most 10sk rerandomizations.
The results are summarized in Table B2. Our first observation is that the values of E(MK) computed
using the TCGA-UCEC dataset are very close to those for an ideal dataset, which are computed using
Lemma 1. This implies that the distribution of D∗k converges to a normal distribution quickly, despite the
fact that the majority of the covariates are binary and some continuous covariates have skewed empirical
distributions. For design (v) (K = 10), the two values for E(MK) differ most because the sample size
of each group is the smallest. Further, although S = 2000 is only moderate considering p = 12, for all
designs the ratios E(M)/E(MK) are not far away from their limits N/nK . Finally, design (iv) produces
a larger value of E(M)/E(MK) than does design (iii), even though both designs have the sample size of
the last group 2nK = 108. The reason is that design (iii) has 2nK−1 = 220 and design (iv) has 2nK−1 =
110, which implies that design (iv) is about twice as efficient as design (iii) in minimizing the expected
Mahalanobis distance of the first 440 subjects. Hence, when entering the rerandomization of the last group,
design (iv) tends to have a much smaller value of MK−1 and thus a smaller MK .
We conclude by applying the randomization procedure of Qin et al. (2016) to this dataset. We first
generate a random permutation of all the individuals and split them into N = 274 groups (each group
contains 2 individuals). Then for the kth group, we try the two possible 1:1 assignments and for each
assignment we compute the Mahalanobis distance of the first 2k individuals; with probability q ∈ (1/2, 1],
we choose the assignment that produces a smaller Mahalanobis distance, and with probability 1− q,
we choose the other. We repeat this procedure 20, 000 times. The sample covariance matrix of all the
individuals is assumed to be known. Using q = 0.75, the suggested value in Qin et al. (2016), the sample
mean of the Mahalanobis distance of the entire dataset after randomization is 0.926 with standard error
4× 10−3, which is better than Morgan–Rubin complete rerandomization but worse than the sequential
schemes we have considered. For comparison, using q = 1, the sample mean of the Mahalanobis distance
of the entire dataset after randomization is 0.228 with standard error 6× 10−4, which is slightly better than
the sequential enrollment design (v). However, note that when q = 1, the procedure becomes deterministic
once the order of all the individuals is fixed. In this case the procedure is very vulnerable to selection bias.
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Table B2: E(M) and E(MK) for TCGA-UCEC dataset
Design N/nK
TCGA-UCEC Ideal dataset
E(MK) E(M)/E(MK) E(MK) E(M)/E(MK)
(i) 1.0 1.627 - 1.627 -
(ii) 3.0 0.723 2.25 0.723 2.25
(iii) 5.1 0.539 3.02 0.536 3.04
(iv) 5.1 0.455 3.58 0.453 3.59
(v) 10.1 0.236 6.90 0.232 7.02
For all designs, we use S = 2000. Design (i) refers to Morgan–Rubin complete rerandomization. Esti-
mates of E(MK) for TCGA-UCEC dataset are obtained from 20, 000 Monte Carlo simulations with
SE/Mean ≈ 0.001. “Ideal dataset” refers to the Monte Carlo experiments using Lemma 1. Estimates
of E(MK) under “Ideal dataset” are obtained from 100, 000 Monte Carlo simulations with SE/Mean
≈ 5× 10−4 (exact for design (i); see Section B·1 for more details). See Table B4 for the values of
s1, . . . , sK .
Table B3: (s1, . . . , sK) used in Figure B1
p S (s1, . . . , s3) (s1, . . . , s5) (s1, . . . , s10)
2 10 (2,2,6) (2,2,2,2,2) (1,1,1,1,1,1,1,1,1,1)
2 20 (2,4,14) (2,2,2,3,11) (2,2,2,2,2,2,2,2,2,2)
2 50 (3,6,41) (3,3,3,6,35) (2,2,2,2,2,2,2,2,4,30)
2 100 (5,9,86) (4,4,4,8,80) (3,3,3,3,3,3,3,3,7,69)
2 200 (5,12,183) (5,5,6,12,172) (4,4,4,4,4,4,4,5,11,156)
2 500 (10,22,468) (8,8,9,20,455) (5,5,5,5,5,5,5,6,17,442)
2 1000 (10,28,962) (10,10,11,28,941) (8,8,8,8,8,8,8,9,26,909)
2 2000 (10,37,1953) (10,10,12,37,1931) (10,10,10,10,10,10,10,12,36,1882)
2 5000 (10,54,4936) (10,10,13,54,4913) (10,10,10,10,10,10,10,13,54,4863)
2 10000 (10,74,9916) (10,10,13,74,9893) (10,10,10,10,10,10,10,13,74,9843)
5 10 (2,3,5) (2,2,2,2,2) (1,1,1,1,1,1,1,1,1,1)
5 20 (2,4,14) (2,2,2,4,10) (2,2,2,2,2,2,2,2,2,2)
5 50 (3,8,39) (3,3,4,8,32) (2,2,2,2,2,2,2,3,6,27)
5 100 (5,14,81) (4,4,5,13,74) (3,3,3,3,3,3,3,4,11,64)
5 200 (5,23,172) (5,6,8,22,159) (4,4,4,4,4,4,4,7,19,146)
5 500 (10,46,444) (8,9,13,43,427) (5,5,5,5,5,5,6,10,41,413)
5 1000 (13,75,912) (10,11,18,72,889) (8,8,8,8,8,8,9,16,69,858)
5 2000 (18,125,1857) (10,12,22,120,1836) (10,10,10,10,10,10,12,22,118,1788)
5 5000 (29,244,4727) (10,13,32,237,4708) (10,10,10,10,10,11,13,31,235,4660)
5 10000 (42,402,9556) (10,15,43,394,9538) (10,10,10,10,10,11,15,43,392,9489)
10 10 (2,3,5) (2,2,2,2,2) (1,1,1,1,1,1,1,1,1,1)
10 20 (2,5,13) (2,2,2,4,10) (2,2,2,2,2,2,2,2,2,2)
10 50 (3,10,37) (3,3,4,9,31) (2,2,2,2,2,2,2,3,8,25)
10 100 (6,19,75) (4,4,6,16,70) (3,3,3,3,3,3,3,6,14,59)
10 200 (10,35,155) (5,6,10,31,148) (4,4,4,4,4,4,5,9,29,133)
10 500 (19,77,404) (8,11,19,71,391) (5,5,5,5,5,6,7,17,68,377)
10 1000 (31,139,830) (10,14,30,129,817) (8,8,8,8,8,9,12,28,126,785)
10 2000 (50,251,1699) (10,17,46,238,1689) (10,10,10,10,10,11,17,45,233,1644)
10 5000 (95,547,4358) (10,24,89,525,4352) (10,10,10,10,11,13,23,88,521,4304)
10 10000 (156,984,8860) (10,33,146,952,8859) (10,10,10,10,11,15,32,145,949,8808)
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Table B4: (s1, . . . , sK) used in Table B2
Design (s1, . . . , sK)
(i) (2000)
(ii) (62, 284, 1654)
(iii) (94, 472, 1434)
(iv) (10, 19, 56, 272, 1643)
(v) (10, 10, 10, 10, 10, 12, 19, 55, 264, 1600)
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APPENDIX C: DETAILS OF THE TCGA-UCEC DATASET
The TCGA-UCEC clinical dataset is available from NCI Genomic Data Commons 1. The dataset con-
tains 73 covariates and 548 subjects. The explanations of the covariates are found from the enrollment
form2. From the 73 covariates, we picked the 12 covariates most likely to be associated with tumor in-
vasion and which had few missing data: days to birth (integer), menopause status (categorical), height
(integer), weight (integer), race (categorical), other malignancy (categorical), histological subtype (cate-
gorical), surgical approach (categorical), peritoneal wash (categorical), tumor grade (categorical), resid-
ual tumor (categorical), total pelvic lnr (integer, lnr: lymph nodes removed). Categorical covariates with
more than two levels were dichotomized according to their corresponding biomedical meanings. For each
covariate, the missing values were imputed by sampling from the observed ones. The distributions of the
twelve covariates are displayed in Figure C1.
Fig. C1: Histograms for the twelve covariates of the TCGA-UCEC dataset.
1 https://gdc.cancer.gov/
2 http://www.nationwidechildrens.org/endometrial-enrollment-form
